1 篇已发布文章 · VMD.
Vimedimex Pharmaceutical (VMD) faces HoSE reprimand for late disclosure on audited 2025 statements, despite 59.9% profit growth, amid audit qualifications and VND 1,578B in receivables.
所有信息仅供参考，不构成投资建议。过往表现不代表未来收益。数据来源于越南公开市场信息。
最后更新: 2026-04-19T15:39:38.845874.